Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

NCT02239731 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Rash Due to Epidermal Growth Factor Receptor Inhibitors

Interventions

DRUG: FDX104 (4% Doxycycline)

Sponsor

Vyne Therapeutics Inc.